Clinical trials: Pituitary Neoplasms
Hyponatremia, Hyponatremic
Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery)
Hyponatremia is defined as sodium below the normal range of 135-145. Symptomatically, it can cause patients to experience a wide range of symptoms including lethargy, headache, nausea, vomiting and in severe cases coma and even…
- Conditions
- Hyponatremia, Hyponatremic, Pituitary Tumor, Pituitary
- Trial name
- DHAPS (NCT03636568)
- Testing
- Fluid Restricted Group
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Any Cancer With Multiple Bone Metastases
Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery
80% of palliative care cancer patients suffer from severe pain. The management of these pain improves the quality of life of these patients. The management of opioid pain refractory to date remains a difficulty for caregivers.
- Trial name
- Hyporadoul (NCT02637479)
- Testing
- GammaKnife®, 18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET), MRI
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Carcinoid Tumor, Acromegaly
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
This study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease
- Trial name
- NCT00446082
- Testing
- Pasireotide
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Basal Ganglia Germinoma, Diabetes Insipidus
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas.
- Conditions
- Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma
- Trial name
- NCT06368817
- Testing
- 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection
- Where
- 115 sites in United States, Australia and 1 more
- Volunteers
- 240 people
- Sponsor
- Children's Oncology Group
Acromegaly Due to Pituitary Adenoma, Acromegaly
Effects of Pasireotide Lar Therapy on Bone Metabolism
Acromegaly, a chronic condition characterized by growth hormone (GH) and, in turn, insulin-like growth factor-1 (IGF-I) excess, is burdened by a series of systemic and metabolic comorbidities that strongly impair quality of life…
- Trial name
- Pasi-Bone (NCT07179926)
- Testing
- morphometric spine radiography
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pituitary Adenoma
Surgical Debulking of Pituitary Adenomas
This is a randomized, multicenter trial with stratification done by a single radiologist at the coordinating center (NYU), and patients with comparable disease will be randomized to Sandostatin LAR treatment administered 1 time…
- Trial name
- NCT01371643
- Testing
- Octreotide LAR, transsphenoidal surgery
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- NYU Langone Health
Pituitary Adenoma
Endocrine Outcome of Surgery for Pituitary Adenoma
Prospective and randomized compare between microsurgical and endoscopic transsphenoidal MRI assisted resection of pituitary adenomas.
- Trial name
- NCT03515603
- Testing
- Endoscopic resection, Microsurgical resection
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- University of Ulm
Resectable, Non-functioning Pituitary Adenoma
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.
- Trial name
- NCT01203618
- Testing
- Farletuzumab
- Where
- United States
- Sponsor
- Morphotek
Pituitary Adenoma
OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.
The aim of the study is to assess accurancy of OCT angiography as a pronostic marker for patients undergoing neurosurgery for compressiver macroadenoma as compared with visual acuity, visual field and OCT.
- Trial name
- FIRST (NCT04074642)
- Testing
- Neurosurgery
- Where
- 2 sites in France
- Volunteers
- 21 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pituitary Tumor, Endocrine Neoplasia
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
The study aims to update current knowledge about the epidemiology of pituitary tumours (PiT), based on the wide body of scientific literature on new familial and/or syndromic forms.
- Conditions
- Pituitary Tumor, Endocrine Neoplasia, Hyperparathyroidism, Solid Tumor
- Trial name
- EpidemioPIT (NCT03973450)
- Testing
- Registration of familial forms and associated neoplasia
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Neuromed IRCCS
Pituitary Tumor, Optic Chiasm Disorder
Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma
Endoscopic endonasal transsphenoidal surgery is a procedure for the treatment of pituitary macroadenomas that cause visual impairment through optic chiasm compression.
- Trial name
- RetroADEN (NCT03363126)
- Testing
- Endonasal transsphenoidal pituitary tumor removal
- Volunteers
- 88 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Acromegaly Due to Pituitary Adenoma
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
In this study, the investigators hypothesize that upfront gamma knife radiosurgery with drug therapy is superior in the treatment of growth hormone-secreting pituitary tumors after primary surgical treatment compared with the…
- Trial name
- MERGE (NCT03439709)
- Testing
- Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Samsung Medical Center
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Pituitary Adenoma, Adrenal Insufficiency
Hydrocortisone Use During Peri-operation for Pituitary Adenomas
The investigators hypothesize that withholding hydrocortisone during the peri-operation in patients with pituitary adenomas whose hypothalamus pituitary adrenal axis are intact are safe.
- Conditions
- Pituitary Adenoma, Adrenal Insufficiency, Surgery
- Trial name
- NCT04621565
- Testing
- Normal saline, Hydrocortisone
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Peking Union Medical College Hospital
Brain Neoplasm, Glioblastoma
Evaluation of Factors in Human Brain Tumors
Presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy).
- Conditions
- Brain Neoplasm, Glioblastoma, Glioma, Pituitary Neoplasm
- Trial name
- NCT00001171
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Craniopharyngioma
Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma
With the preliminary anatomical and histological study, the membranous structures of the sellar region was considered to be closely related with the growth pattern of Craniopharyngiomas(CP).
- Trial name
- NCT00949156
- Testing
- Different surgical approach and techniques being used to treat three subtype of CP
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Southern Medical University, China
Pituitary Tumor
Postoperative Cognitive Dysfunction in Patients Undergoing Pituitary Removal Surgery
As postoperative cognitive dysfunction rates are high especially in elder patients, cognitive dysfunction is not diagnosed and treated effectively.
- Trial name
- NCT03719781
- Testing
- standardized minimental testing
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Kocaeli University
Cavernous Sinus Meningioma, Pituitary Adenoma
Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory
Several studies showed that radiotherapy as brain tumors treatment may affect cognition. It was observed that durable memory impairments could arise at irradiated patients if radiotherapy is applied on medial temporal lobes.
- Trial name
- ISOMAB (NCT02750371)
- Testing
- Evaluation of autobiographical memory
- Where
- France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Bordeaux
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University